Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May;36(5):1046-1052.
doi: 10.1111/jce.16645. Epub 2025 Mar 19.

One-Year Success Rates of a Stable, Low Pressure Cryoballoon for the Treatment of Paroxysmal Atrial Fibrillation: Results of the Prospective, International, Multicenter POLAR ICE Study

Armin Luik  1 , Ante Anic  2 , Claire A Martin  3 , Roland R Tilz  4 , S C Yap  5 , Carlo de Asmundis  6 , Laure Champ-Rigot  7 , Saverio Iacopino  8 , Phillip Sommer  9 , Elizabeth M Albrecht  10 , Jonathan D Raybuck  10 , Elizabeth Richards  10 , Nele Cielen  10 , Pascal Defaye  11
Affiliations
Multicenter Study

One-Year Success Rates of a Stable, Low Pressure Cryoballoon for the Treatment of Paroxysmal Atrial Fibrillation: Results of the Prospective, International, Multicenter POLAR ICE Study

Armin Luik et al. J Cardiovasc Electrophysiol. 2025 May.

Abstract

Introduction: Pulmonary vein isolation (PVI) using a cryoballoon is well-established for the treatment of paroxysmal atrial fibrillation (PAF). Compared to other available technologies, the usage of a stable, low-pressure cryoballoon (POLARx, Boston Scientific) has demonstrated lower nadir temperatures and longer thawing times. However, 1-year efficacy and safety still needs to be proven. The aim of the POLAR ICE Study was to evaluate 1-year efficacy and safety outcomes of cryoballoon ablation in patients with paroxysmal atrial fibrillation.

Methods: POLAR ICE, a prospective, non-randomized, international, multicenter study to examine safety and efficacy of the novel cryoballoon for paroxysmal atrial fibrillation and de novo PVI, enrolled 399 patients across 19 centers, between August 2020 and May 2021, of which 11 were redo patients (previous treatment in the LA) and 10 were non-PAF patients.

Results: This study treated 391 patients with the novel cryoballoon. After 12 months, freedom from atrial fibrillation could be demonstrated in 88.1% and freedom from any arrhythmia in 83.5%. Long-term primary composite safety events occurred in four (1.0%) patients, including one (0.26%) death (9.5 months post-index, cause unknown), one (0.26%) stroke, one (0.26%) myocardial infarction, and one (0.26%) persistent PNP (0.26%). AAD usage showed a significant decrease over the course of the study. Biophysical parameters nadir temperature (p = 0.008) and thaw time (p = 0.053) were predictive of 12-month freedom from recurrence.

Conclusion: In this prospective, non-randomized, international, multicenter study, isolation of the pulmonary veins using a stable, low pressure cryoballoon was highly effective and safe in patients treated for paroxysmal atrial fibrillation.

Keywords: atrial fibrillation; catheter ablation; clinical.

PubMed Disclaimer

References

    1. G. Hindricks, T. Potpara, N. Dagres, et al., “2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio‐Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed With the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC,” European Heart Journal 42 (2021): 373–498, https://doi.org/10.1093/eurheartj/ehaa612.
    1. R. Providencia, P. Defaye, P. D. Lambiase, et al., “Results From a Multicentre Comparison of Cryoballoon vs. Radiofrequency Ablation for Paroxysmal Atrial Fibrillation: Is Cryoablation More Reproducible?,” Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology 19 (2017): 48–57, https://doi.org/10.1093/europace/euw080.
    1. C. A. Martin, R. R. R. Tilz, A. Anic, et al., “Acute Procedural Efficacy and Safety of a Novel Cryoballoon for the Treatment of Paroxysmal Atrial Fibrillation: Results From the POLAR ICE Study,” Journal of Cardiovascular Electrophysiology 34 (2023): 833–840, https://doi.org/10.1111/jce.15861.
    1. K. H. Kuck, J. Brugada, A. Fürnkranz, et al., “Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation,” New England Journal of Medicine 374 (2016): 2235–2245, https://doi.org/10.1056/NEJMoa1602014.
    1. J. G. Andrade, G. A. Wells, M. W. Deyell, et al., “Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation,” New England Journal of Medicine 384 (2021): 305–315, https://doi.org/10.1056/NEJMoa2029980.

Publication types

MeSH terms